Following an extension of its partnership agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, Aptamer Group has announced the development of new drug conjugates for use as precision chemotherapeutics. Click to read more.
/PRNewswire/ Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused.
- Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors - MRG004A selected for clinical development based